First multiple myeloma patient dosed with a SLAM-F7/CS1 specific CAR-T cell product employing T-CURX' proprietary Sleeping Beauty transposon gene-transfer technology.
Today, T-CURX announces the start of a phase I/II clinical trial in the Horizon-2020 EU-funded research project "CARAMBA", in which T-CURX is an SME (small, medium-sized enterprise) partner and beneficiary.
The CARAMBA consortium is an international consortium of 11 European Partners from 6 European countries, which aims to develop a novel CAR-T cell product for multiple myeloma patients leveraging T-CURX' proprietary non-viral gene transfer technology using the Sleeping Beauty transposon. The project was awarded a 5-year € 6.1 M Horizon 2020 grant in 2018, called CARAMBA.
The CAR-T cell product developed in the CARAMBA project is targeting the multiple myeloma target SLAM-F7/CS1, which is uniformly expressed on cells from all multiple myeloma patients. The first patient included in the First-in-Human SLAM-F7/CS1 CAR-T cell study was enrolled at the University Clinics of Würzburg, Germany. It is the primary endpoint of the phase I part of the clinical trial to assess the safety of the novel CAR-T cell product in multiple myeloma patients and to determine the maximal tolerated dose (MTD) and recommended phase II dose (RP2D) for this novel CAR-T cell product. More information about the clinical trial can be found at https://clinicaltrials.gov/ under clinical trial number: NCT04499339.